Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 7/20 | 0.70 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.70 |
| ▸ | BCHE | P06276 | 13/20 | 0.65 |
| ▸ | ACHE | P22303 | 12/20 | 0.65 |
| ▸ | BACE1 | P56817 | 12/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271477 | 0.93 | VEGFA (0.76) | VEGFAEGLN1BCHEACHEBACE1 | |
| SCHEMBL19478697 | 0.86 | EGLN1 (0.78) | VEGFAEGLN1BCHEACHEBACE1 | |
| SCHEMBL278141 | 0.84 | EGLN1 (0.79) | VEGFAEGLN1BCHEACHEBACE1 | |
| SCHEMBL21667234 | 0.83 | VEGFA (0.62) | VEGFAEGLN1BCHEACHEBACE1 | |
| SCHEMBL272935 | 0.82 | EGLN1 (1.00) | VEGFAEGLN1BCHEACHEBACE1 | |
| SCHEMBL277620 | 0.82 | EGLN1 (0.71) | VEGFAEGLN1BCHEACHEBACE1 | |
| SCHEMBL12649394 | 0.81 | VEGFA (0.70) | VEGFAEGLN1BCHEACHE | |
| SCHEMBL16789163 | 0.81 | EGLN1 (0.78) | VEGFAEGLN1BCHEACHEBACE1 | |
| SCHEMBL15255387 | 0.81 | EGLN1 (0.70) | VEGFAEGLN1ACHE | |
| SCHEMBL278202 | 0.80 | VEGFA (1.00) | VEGFAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496082-B1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | claimed |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | claimed |
| US-8999971-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2015-04-07 | — | — | US | claimed |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2014-12-11 | — | — | US | claimed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | claimed |
| EP-2496082-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | claimed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | claimed |
| WO-2011057112-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | claimed |
| EP-1558579-B1 | N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIALS | PROCTER & GAMBLE (US) | 2007-09-12 | — | — | EP | claimed |
| EP-1558579-A1 | N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-03 | — | — | EP | claimed |
| WO-2004043927-A1 | N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 2004-05-27 | — | — | WO | claimed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | claimed |
| CN-116018136-A | Hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of aging-related disorders | 百爱及生物医药公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20210353612-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | BioAge Labs, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-6930117-B2 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-16 | — | — | US | disclosed |
| EP-1558579-A1 | N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004043927-A1 | N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885BCHE 4608/4885 |
| US-20210353612-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | HIF1AN, HIF1A, P4HA1 | VEGFA 384/4885EGLN1 11/4885BCHE 2154/4885 |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | VEGFA 3112/4885EGLN1 926/4885BCHE 2549/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885BCHE 3282/4885 |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885BCHE 4608/4885 |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885BCHE 4608/4885 |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885BCHE 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.